Last reviewed · How we verify
Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim
This is a Phase 1, single-centre, fixed-sequence, open label, drug-drug interaction study in 2 groups of healthy subjects. Group A: to evaluate the effects of itraconazole, a strong inhibitor of cytochrome P450 3A (CYP3A), upon the pharmacokinetics of olorofim . Group B: t o evaluate the effects rifampicin, a strong inducer of CYP3A, upon the pharmacokinetics of olorofim .
Details
| Lead sponsor | F2G Biotech GmbH |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 24 |
| Start date | Mon Nov 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Feb 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Healthy
Interventions
- Itraconazole oral solution
- Rifampicin Oral Capsule
- Olorofim
Countries
United Kingdom